June 12, 2023 11:03 AM EDT

FDA sets action date for Phathom after trace carcinogens led to CRL, grants AstraZeneca priority review

Paul Schloesser

Associate Editor

Lei Lei Wu

News Reporter

Following a rejection in February, the FDA will take another look at Phathom Pharmaceuticals’ gastroesophageal reflux disease (GERD) treatment, the biotech

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA sets action date for Phathom after trace carcinogens led to CRL, grants AstraZeneca priority review

Paul Schloesser

Associate Editor

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

AstraZeneca culls Phase 2 opioid use disorder drug

Are programs with compounded GLP-1s safe for your population?

FDA sets ac­tion date for Phath­om af­ter trace car­cino­gens led to CRL, grants As­traZeneca pri­or­i­ty re­view

Associate Editor

News Reporter

Sign up to read this article for free.

FDA sets action date for Phathom after trace carcinogens led to CRL, grants AstraZeneca priority review